PUBLISHER: The Business Research Company | PRODUCT CODE: 1957548
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957548
An oral vaccine is a type of immunization administered through the mouth-typically in liquid, tablet, or capsule form-to stimulate an immune response against specific pathogens. These vaccines introduce antigens via the gastrointestinal tract, enabling the immune system to recognize and respond effectively to the targeted disease.
The main types of oral vaccines include live attenuated vaccines, inactivated vaccines, subunit vaccines, and others. Live attenuated vaccines contain weakened forms of pathogens that trigger a strong immune response without causing the disease. Oral vaccines are applied for the prevention of diseases such as polio, tuberculosis, rabies, influenza, cholera, and more. Key end users include hospitals, clinics, government health organizations, and other healthcare providers.
Tariffs have impacted the oral vaccine market by increasing costs of imported vaccine antigens, excipients, and packaging materials, affecting vaccine manufacturing and distribution. Segments like live attenuated and inactivated vaccines are most affected, particularly in regions such as North America, Europe, and Asia-Pacific. This has led to higher treatment costs and potential delays in immunization programs. On the positive side, tariffs have encouraged local vaccine production, investment in domestic manufacturing infrastructure, and innovation in vaccine delivery technologies.
The oral vaccine market research report is one of a series of new reports from The Business Research Company that provides oral vaccine market statistics, including oral vaccine industry global market size, regional shares, competitors with a oral vaccine market share, detailed oral vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the oral vaccine industry. This oral vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The oral vaccine market size has grown strongly in recent years. It will grow from $3.95 billion in 2025 to $4.35 billion in 2026 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to prevalence of vaccine-preventable diseases, rising awareness of immunization benefits, government vaccination initiatives, development of oral polio and cholera vaccines, growth of hospital and clinic vaccination programs.
The oral vaccine market size is expected to see strong growth in the next few years. It will grow to $6.29 billion in 2030 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to launch of novel oral vaccines (dna, rna, vlp), expansion of global immunization programs, integration of digital health and monitoring tools, rising investment in vaccine research and development, increased focus on adult and travel vaccinations. Major trends in the forecast period include rising adoption of oral vaccines for pediatric immunization, increasing focus on preventive healthcare and mass vaccination programs, development of live attenuated and subunit oral vaccines, expansion of government-funded immunization campaigns, integration of cold chain and logistics innovations for vaccine distribution.
The escalating prevalence of infectious diseases is set to boost the oral vaccine market in the coming years. Infectious diseases stem from pathogenic microbes like bacteria, viruses, fungi, or parasites, spreading person-to-person or via surroundings. Their surge links to intensified global mobility, swiftly ferrying people and germs across frontiers and amplifying worldwide outbreaks. Oral vaccines excel against infectious diseases by triggering gut mucosal immunity-a key invasion route for many pathogens-delivering robust on-site defense. For example, in May 2025, the UK Health Security Agency reported an 11.0% rise in England's tuberculosis (TB) cases in 2023 versus 2022. Thus, the climbing tide of infectious diseases is fueling the oral vaccine market.
Leading firms in the oral vaccine market are advancing cutting-edge options like second-generation oral pill vaccines to amplify immune activation and simplify delivery. A second-generation pill-based oral vaccine boosts antibody production, extends coverage, and facilitates widespread vaccination sans needles or refrigeration. For instance, in March 2025, Vaxart Inc., a US biotechnology company, kicked off a Phase 1 trial for its upgraded oral norovirus vaccine in pill form. The study assesses enhanced immunity and safety of the refined versions, targeting the persistent worldwide demand for practical norovirus protection. Its pill design eliminates injection hurdles and enables swift, broad deployment, especially amid epidemics.
In March 2024, the International Vaccine Institute (IVI), a South Korea-based non-profit advancing global vaccines, allied with Biological E. Limited to produce a streamlined oral cholera vaccine (OCV-S) for India and beyond. This collaboration lets IVI share expertise to guide clinical trials and approvals, yielding affordable oral cholera shots. Tech transfer wraps up by 2025 to counter surging global cholera threats. Biological E. Limited is an India-based oral vaccine producer.
Major companies operating in the oral vaccine market are Panacea Biotec Ltd., Zydus Lifesciences, Serum Institute of India Pvt. Ltd., Bharat Biotech Ltd., Haffkine Biopharmaceutical Co. Ltd., Medigen Vaccine Biologics Corp., BlueWillow Biologics Inc.
North America was the largest region in the oral vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the oral vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The oral vaccine market consists of sales of oral booster doses, oral vaccine delivery systems, vaccine stabilizers, and mucosal immunology research tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Oral Vaccine Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses oral vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for oral vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oral vaccine market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.